Synthesis and Pharmacological Activity of a Series of Dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a Novel Class of Potent Cognition Enhancers

Journal of Medicinal Chemistry

Volumn 36, Issue 26, 1993, Pages 4214-4220

  Pinza, Mario ^a,b   Farina, Carlo ^a   Cerri, Alberto ^a   Pfeiffer, Ugo ^a,c   Riccaboni, Maria T ^a   Banfi, Silvano ^a   Biagetti, Raffaella ^a   Pozzi, Ottorino ^a   Magnani, Maurizio ^a,b   Dorigotti, Luciano ^a,b  

^a Research Laboratories ^*  (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^c Flli Lamberti ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDINONE; DIHYDRO 1H PYRROLO[1,2 A]IMIDAZOLE 2,5(3H,6H) DIONE; DIMIRACETAM; NOOTROPIC AGENT; OXIRACETAM; PIRACETAM; SCOPOLAMINE BROMIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0027771510     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00078a011     Document Type: Article

References (45)

1. Moos, W. H.; Davis, R. E.; Schwarz, R. D.; Gamzu, E. R. Cognition activators. Med. Res. Rev. 1988, 8, 353.
2. Merlini, L.; Pinza, M. Trends in searching for new cognition enhancing drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1989, 13 (Suppl.), 61.
3. Frostl, W.; Maitre, L. The families of cognition enhancers. Pharmacopsychiatry 1989, 22, 54.
4. Nicholson, C. D. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990, 101, 147.
5. Giurgea, C. E. In Fundamentals to a pharmacology of the mind, C. Thomas Publ.: Springfield; 1981.
6. Ponzio, F.; Pozzi, O.; Banfi, S.; Dorigotti, L.; Brain entry and direct pharmacological effects of the nootropic drug oxiracetam. Pharmacopsychiatry 1989, 22 Suppl., 111.
7. Itil, T. M.; Menon, G. M.; Songar, A.; Itil, K. Z.; CNS pharmacology and clinical therapeutic effects of oxiracetam. Pharmacopsychiatry 1989, 22, S70.
8. Satoh, M.; Ishihara, K.; Iwama, T.; Takagi, H. Aniracetam augments, and midazolam inhibits, the long-term potentiation in guinea pig hippocampal slices. Neurosci. Lett. 1986, 68, 216.
9. Spignoli, G.; Pepeu, G. Interaction between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol. Biochem. Behav. 1987, 27, 491.
10. Marchi, M.; Besana, E.; Raiteri, M. Oxiracetam increases the release of endogenous glutamate from depolarized hippocampal slices. Eur. J. Pharmacol. 1990, 185, 247.
11. Pugliese, A. M.; Corradetti, R.; Ballerini, L.; Pepeu, G. Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices. Br. J. Pharmacol. 1990, 99, 189.
12. Pifferi, G.; Pinza, M. Cyclic GABA-GABOB analogues I—Synthesis of new 4-hydroxy-2-pyrrolidinone derivatives. Farmaco Ed. Sci. 1977, 32, 602.
13. Banfi, S.; Fonio, W.; Allievi, E.; Pinza, M.; Dorigotti, L. Cyclic GABA-GABOB analogues IV—Activity on learning and memory. Farmaco Ed. Sci. 1984, 39, 16.
14. Garvey, D. S.; May, P. D.; Nadzan, A. M. 3,4-Disubstituted γ-lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine. J. Org. Chem. 1990, 55, 936 and references cited therein.
15. Pinza, M.; Farina, C.; Banfi, S.; Pfeiffer, U. Pharmacologically active 5-oxo-1-imidazolidineacetamide compounds. U.S. Patent 4,719,222; Chem. Abstr. 1987, 107, 59481. Compound 2 significantly reversed ECS-induced amnesia in mice by 32% at 10 mg/kg ip; oxiracetam's effect was observed only at 60 mg/kg ip (35% reversal).
16. Pinza, M.; Farina, C.; Banfi, S.; Pfeiffer, U. Nootropic imidazolidinones. U.S. Patent 4,703,0954; Chem. Abstr. 1987, 106, 138445. Compound 3 significantly reversed ECS-induced amnesia in mice by 47% at 10 mg/kg i.p.
17. Pinza, M.; Pfeiffer, U. Process for the preparation of pyrrolidinone derivatives. U.S. patent 4,797,496; Chem. Abstr. 1986, 104, 68751.
18. 4 antagonist activity of 2-norleukotriene analogues. J. Med. Chem. 1985, 28, 1847.
19. Pellegata, R.; Pinza, M.; Pifferi, G. An improved synthesis of γ-, δ-, and ϵ-lactams. Synthesis 1978, 614.
20. Pfeiffer, U.; Riccaboni, M. T.; Erba, R.; Pinza, M. A short synthesis of 4-imidazolidinone. Liebigs Ann. Chem. 1988, 993.
21. Schindler, U. Pre-clinical evaluation of cognition enhancing drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1989, 13 (Suppl.), 99.
22. Banfi, S.; Dorigotti, L.; Experimental behavioral studies with oxiracetam on different types of chronic cerebral impairment. Clin. Neuropharmacol. 1986, 9 (Suppl. 3), S19.
23. Sarter, M.; Hagan, J.; Dudchenko, P.; Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part 1. Psychopharmacology 1992, 107, 144.
24. Sarter, M.; Hagan, J.; Dudchenko, P.; Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part 2. Psychopharmacology 1992, 107, 461.
25. Banfi, S.; Cornelli, U.; Fonio, W.; Dorigotti, L. A screening method for substances potentially active on learning and memory. J. Pharmacol. Methods 1982, 8, 255.
26. Pozzi, O.; Allievi, E.; Biagetti, R; Banfi, S.; Dorigotti, L. Behavioural screening for potential nootropic drugs. Pharmacol. Res. Commun. 1988, 20 (Suppl. 2), 315.
27. Butler, D. E.; Nordin, I. C.; L'Italien, Y. J.; Zweisler, L.; Poschel, P. H.; Marriott, J. G. Amnesia-reversal activity of a series of n-[(disubstituted-amino)alkyl]-2-oxo-l-pyrrolidineacetamides, including pramiracetam. J. Med. Chem. 1984, 27, 684.
28. Butler, D. E.; Leonard, J. D.; Caprathe, B. W.; L'Italien, Y. J.; Pavia, M. R.; Hershenson, F. M.; Poschel, P. H.; Marriott, J. G. Amnesia—Reversal activity of a series of cyclic imides. J. Med. Chem. 1987, 30, 498.
29. Angelucci, L.; Calvisi, P.; Catini, R.; Cosentino, U.; Cozzolino, R.; De Witt, P.; Ghirardi, O.; Giannessi, F.; Giuliani, A.; Guaraldi, D.; Misiti, D.; Ramacci, M. T.; Scolastico, C.; Tinti, M. O. Synthesis and amnesia-reversal activity of a series of 7- and 5-membered 3-acylamino lactams. J. Med. Chem. 1993, 36, 1511.
30. Pepeu, G.; Marconcini-Pepeu, I.; Casamenti, F.; The validity of animal models in the search for drugs for the aging brain. Drug Des. Delivery 1990, 7, 1.
31. Rusted, J. M.; Warburton, D. Effects of scopolamine on verbal memory; a retrival or acquisition deficit? Neuropsychobiology 1989, 21, 76.
32. Wesnes, K.; Simpson, P. M.; Kidd, A. The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 977) in man. Med. Sci. Res. 1987, 15, 1063.
33. Bartus, R. T.; Dean, R. L., III; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408.
34. Shutske, G. M.; Pierrat, F. A.; Kapples, K. J.; Cornfeldt, M. L.; Szewczak, M. R.; Huger, F. P.; Bores, G. M.; Haroutunian, V.; Davis, K. L. (±)-9-Amino-1,2,3,4-tetrahydroacridin-1-ols. A potential Alzheimer's disease therapeutic of low toxicity. J. Med. Chem. 1988, 31, 1278.
35. Shutske, G. M.; Pierrat, F. A.; Kapples, K. J.; Cornfeldt, M. L.; Szewczak, M. R.; Huger, F. P.; Bores, G. M.; Haroutunian, V.; Davis, K. L. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. J. Med. Chem. 1989, 32, 1805.
36. Chopin, P.; Briley, M. Effect of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 1992, 106, 26.
37. FDA committee endorses Warner-Lambert's tacrine. Scrip 1993, March 26, 19.
38. Irwin, S. Comprehensive observational assessment: Ia. A systematic quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacology (Berlin) 1968, 13, 222.
39. Magnani, M.; Pozzi, O.; Biagetti, R.; Banfi, S.; Dorigotti, L.; Oxiracetam antagonizes the disruptive effect of scopolamine on memory in the radial maze. Psychopharmacology 1992, 106, 175.
40. Yang, P. S.; Rising, M. M. A simplified method of preparation of alpha amino acids amides. J. Am. Chem. Soc. 1931, 53, 3183.
41. Smith, E. L.; Spackman, D. H. Specificity of leucine ami-nopeptidase. V. Activation, specificity, and mechanism of action. J. Biol. Chem. 1955, 212, 271.
42. Marples, B. A.; Saint, C. G.; Traynor, J. R. Regiochemistry of nucleophilic opening of β-substituted styrene oxides with thiolate anions: model experiments in the synthesis of leukotriene analogues. J. Chem. Soc. Perkin Trans. 1, 1986, 567.
43. Gannett, P. M.; Nagel, D. L.; Reily, P. J.; Lawson, T.; Sharpe, J.; Toth, B. The capsaicinoids: Their separation, synthesis, and mutagenicity. J. Org. Chem. 1988, 53, 1064.
44. Jarwik, M. E.; Kopp, R. An improved one-trial passive avoidance learning situation. Psychol. Rev. 1967, 21, 221.
45. Metha, C. R.; Pathel, N. R. A network algorithm for performing Fisher's exact test in r × c contingency tables. J. Am. Stat. Assoc. 1983, 78, 427. The software employed was SAS Stat. Rel. 6.3, available from SAS Institute.